TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS

Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treatment of patients with wide-spread and incurable canc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: T. Y. SEMIGLAZOVA, A. S. ZHABINA, А. V. BELYAEVA, V. A. KLUGE, K. V. USOVA, D. H. LATIPOVA, G. M. TELETAEVA, A. V. NOVIK, A. I. SEMENOVA, S. A. PROTSENKO
Format: Artigo
Jezik:Russo
Izdano: Remedium Group LLC 2016-12-01
Serija:Медицинский совет
Teme:
itk egfr
pfs
quality of life
nsclc mut +
afatinib
Online pristup:https://www.med-sovet.pro/jour/article/view/1406
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items